Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
UK: More health is associated with more cardiovascular disease (CVD) and higher triglycerides...
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
Glioblastoma cells can 'unstick' from their neighbors to become more deadly
2.
Study finds 81% of cancer cures touted by TikTok videos are fake
3.
Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.
4.
Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?
5.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
1.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
2.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
3.
A New Perspective on Spherocytosis: Uncovering Innovative Treatments
4.
Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell
5.
Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Navigating the Complexities of Ph Negative ALL - Part VII
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge